Multiple Ascending Doses Study to Evaluate the Tolerability and Pharmacokinetics of SPH3127 in Chinese Healthy People

Trial Profile

Multiple Ascending Doses Study to Evaluate the Tolerability and Pharmacokinetics of SPH3127 in Chinese Healthy People

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs SPH 3127 (Primary)
  • Indications Hypertension
  • Focus Adverse reactions
  • Sponsors Shanghai Pharmaceuticals Holding
  • Most Recent Events

    • 27 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 24 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top